News | April 12, 2024
CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
A significant proportion of healthcare professionals still tend to favor branded drugs
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)